Product Introduction: EMPAWORTH L 25/5

EMPAWORTH L 25/5 is an advanced combination oral hypoglycemic medication manufactured by Dr. Morepen. Composed of 25mg of Empagliflozin (an SGLT2 inhibitor) and 5mg of Linagliptin (a DPP-4 inhibitor), it is indicated for glycemic control in adult patients diagnosed with Type 2 Diabetes Mellitus, helping lower blood glucose levels through complementary insulin-independent and insulin-dependent pathways.

Primary Indications

• Management of Type 2 Diabetes Mellitus in adults for optimal glycemic control.
• Improving insulin secretion, reducing insulin resistance, and restricting glucose reabsorption.
• Reducing the long-term risk of diabetic microvascular and macrovascular complications.

Clinical Benefits

• Weight & BP Reductions: Empagliflozin aids in moderate calorie loss and blood pressure reduction through glucosuria.
• HbA1c Control: Synergistic action yields robust reductions in both fasting and post-meal blood sugar levels.
• Cardioprotection: Empagliflozin offers proven benefits in reducing cardiovascular death in diabetic patients.

Possible Side Effects

Common side effects may include:

• Genitourinary tract infections (such as vulvovaginal candidiasis or urinary tract infections) due to glucose in urine.
• Nasopharyngitis, headache, or dizziness.
• Dehydration, orthostatic hypotension, or increased urination.

How to Take EMPAWORTH L 25/5

• Take the tablet once daily, preferably in the morning, with or without food.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Maintain adequate hydration to prevent dehydration and urinary tract infections.

Mechanism of Action

EMPAWORTH L 25/5 works through two complementary mechanisms:

• Empagliflozin: Inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion.
• Linagliptin: Inhibits dipeptidyl peptidase-4 (DPP-4) enzyme, increasing active incretin hormone levels (GLP-1 and GIP) to stimulate insulin release and suppress glucagon.

Safety Warnings

• Renal Function: Empagliflozin efficacy is dependent on kidney function. Avoid in severe renal impairment.
• Diabetic Ketoacidosis (DKA): SGLT2 inhibitors carry a rare risk of atypical euglycemic DKA. Monitor symptoms.
• Pregnancy & Nursing: Strictly contraindicated. Avoid use.

Patient Advice

• Maintain high standards of personal hygiene to prevent genital fungal infections.
• Drink plenty of water (8-10 glasses) daily to stay well-hydrated.
• Ensure regular monitoring of kidney function, electrolytes, and HbA1c levels.

Fact Box

Drug Interactions

• Insulin & Sulfonylureas: Concomitant use increases the risk of hypoglycemia; lower doses may be required.
• Diuretics (Loop): May increase the risk of dehydration and hypotension.

User Feedback

• Patients report excellent control of blood glucose levels, with many noting beneficial weight loss and cardiovascular stability.
• Highly recommended by endocrinologists as a premium oral combination option.